NightHawk Biosciences Inc (NHWK)

[dia76ca]

Heat Biologics Selects Adaptive Biotechnologies to Discover Potential Clinical Biomarkers to Advance Novel Immunotherapies

Today : Tuesday 11 October 2016


Heat Biologics, Inc. (Nasdaq:HTBX), announced that they have advanced their biomarker discovery collaboration with Adaptive Biotechnologies.  Adaptive will use its patented immune profiling assay, immunoSEQ™, to enable an in-depth characterization of the immune response to Heat’s ImPACT and ComPACT-based immunotherapies, including HS-410, Heat’s Phase 2 product candidate for non-muscle invasive bladder cancer. The immunoSEQ Assay, when used to evaluate the mechanism of action of the ImPACT platform, provides a significant biomarker identification opportunity to better select patients and accelerate future enrollment based on immune status.   

“Previously reported data using Adaptive’s immunoSEQ Assay, demonstrated a trend between established anti-tumor immune responses and clinical outcomes with HS-410,” stated Taylor Schreiber, M.D., Ph.D., Heat’s Chief Scientific Officer. “The Adaptive Assay allows us to quantify the clonality of a T-cell response generated by our ImPACT platform. Future work should continue to be fruitful as we advance our understanding of the patients that benefit most from treatment.”